Yangtze University

The study investigates serum RGS10 expression in acute pancreatitis (AP) patients and its prognostic value.

Serum samples and clinical data were collected from 104 AP patients and 34 healthy controls (HC). Whole transcriptome sequencing was performed on serum samples from three randomly selected individuals per group.

Serum RGS10 levels were significantly higher in the moderately severe acute pancreatitis (MSAP) group compared to the mild acute pancreatitis (MAP) and HC (P < 0.01). RGS10 expression was positively correlated with BISAP score, CTSI, INR, PCT, BUN, and Cr. Univariate and multivariate regression analyses identified RGS10, hydrothorax, and Ca²⁺ as independent risk factors for MSAP. RGS10 demonstrated the highest predictive accuracy for MSAP, with an accuracy of 80.0 %, sensitivity of 78.0 %, specificity of 74.1 %. Combining these indicators enhanced the predictive efficacy, achieving an accuracy of 91.2 %, sensitivity of 92.7 %, specificity of 76.3 %. Follow-up data indicated that RGS10, Cr, D-dimer, CTSI, PTAR, PLR, BUN, PT, INR, and disease severity were risk factors for recurrence AP.

RGS10 may serve as a novel biomarker for AP severity and recurrence risk.

African swine fever (ASF) is a highly contagious and severe infectious disease caused by African swine fever virus (ASFV). The disease significantly threatens the sustainable development of the global pig industry. Unfortunately, to date, no safe and efficacious vaccines are commercially available except in Vietnam. Antioxidative stress is a critical factor in antiviral strategies. In this study, we show that ASFV infection elevates the level of reactive oxygen species (ROS) and suppresses the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway in vitro and in vivo. Moreover, overexpressing Nrf2 can significantly inhibit ASFV replication. Through high-throughput screening of natural small molecules against ASFV, we identify resveratrol (RES), an Nrf2 activator, as a compound capable of inducing the cellular antiviral responses and effectively inhibiting ASFV replication in primary porcine alveolar macrophages (PAMs). Notably, untargeted metabolomics profiling reveals that glutathione emerges as a primary differential metabolite related to the antiviral activities of RES against ASFV. Mechanistically, RES exerts its antiviral effects and attenuates the elevated level of ROS caused by ASFV infection by inducing the production of reduced glutathione (GSH) via the activation of the Nrf2 signaling pathway. In conclusion, RES exhibits broad efficacy as a potentially effective compound for inhibiting ASFV infection and alleviating the oxidative stress induced by ASFV infection via the Nrf2 signaling pathway.

High-risk gastrointestinal stromal tumors (GISTs) are highly heterogeneous. This study aimed to developa nomogram for predicting recurrence in patients with high-risk GISTand to provide guidance for adjuvant therapy.

Data were retrospectively collected from 971 patients with high-risk GIST who underwent genetic testingat 13 centers in China. A nomogram was constructed in the training cohort and validated in the validation cohort.

The training and validation cohorts included 696 and 275 patients, respectively. The nomogram incorporated blood plateletlevels, total protein, tumor location, tumor size, mitotic count, tumor rupture, Ki-67 index, and gene mutations. The C-index and AUC were 0.758 and 0.781 in the training cohort and 0.841 and 0.755, respectively, in the validation cohort. Calibration and DCA curves confirmed favorable discrimination, calibration accuracy, and clinical benefits. Using the nomogram, patients were categorized into a general high-risk groupand a very high-risk group. Among the general high-risk group, no significant difference in RFS was observed between patients who received adjuvant imatinib for 2.5 years or longer. Conversely, in the very high-risk group, patients receiving adjuvant imatinib for five or more years had markedly improved RFS.

Based on the largest nomogram-related multicenter study in high-risk GIST, the nomogram accurately predicted RFS in patients with high-risk GIST and provided guidance on adjuvant therapy for the first time. For general high-risk patients, 3 years of adjuvant imatinib is adequate, whereas very high-risk patients benefit significantly from more than 5 years of adjuvant imatinib.